Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Selten Pharma Inc.
DescriptionFixed-dose combination of SPI-026, a bone morphogenetic protein receptor type II) pathway activator, and a phosphodiesterase-5 (PDE-5) inhibitor
Molecular Target Bone morphogenetic protein receptor type II (BMPRII) ; Phosphodiesterase-5 (PDE-5)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationHypertension
Indication DetailsTreat pulmonary arterial hypertension (PAH)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today